Grade II astrocytomas are subgrouped by chromosome aberrations

被引:43
作者
Hirose, Y
Aldape, KD
Chang, S
Lamborn, K
Berger, MS
Feuerstein, BG [1 ]
机构
[1] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94115 USA
[2] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94115 USA
[3] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94115 USA
[4] Univ Calif San Francisco, Div Neuropathol, Brain Tumor Res Ctr, San Francisco, CA 94115 USA
[5] Univ Calif San Francisco, Canc Genet Program, San Francisco, CA 94115 USA
关键词
D O I
10.1016/S0165-4608(02)00791-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Grade II astrocytoma is defined as a low-grade tumor, yet patients have a wide range of survival and tumors can quickly progress to high-grade astrocytoma/glioblastoma. Previous studies using comparative genomic hybridization (CGH) failed to demonstrate frequent copy number aberrations (CNA) in these tumors. This may be related to technical difficulties because infiltrating astrocytic tumors are often intermixed with normal brain tissue. We developed methods to exclude most normal tissue and use small amounts of DNA for CGH by microdissecting small regions of tumor from paraffin sections and amplifying extracted DNA using degenerate oligonucleotide-primed polymerase chain reaction (DOP-PCR). Using this method, we examined 30 grade II astrocytoma cases. We found CNA in 25 cases (83%), with a mean of two CNA per case. The most frequent CNA were gains on 7q (12 cases), 5p (5 cases), 9 (5 cases), and 19p (3 cases), and losses on 19q (7 cases), 1p (6 cases), and Xp (3 cases). Gain on 7q and losses on 1p/19q were mutually exclusive. This is the first report on the genetic characterization of low-grade astrocytomas using CGH from microdissected and formalin-fixed tissue. The comparatively large number of cases in this study allows us to suggest that these tumors are genetically subgrouped. (C) 2003 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 53 条
[1]  
Aldape K, 2000, CANCER-AM CANCER SOC, V88, P2342, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2342::AID-CNCR19>3.0.CO
[2]  
2-X
[3]  
[Anonymous], 2000, World Health Organisation Classification of Tumours: Pathology and genetics of tumours of the nervous system
[4]   Radiation response and survival time in patients with glioblastoma multiforme [J].
Barker, FG ;
Prados, MD ;
Chang, SM ;
Gutin, PH ;
Lamborn, KR ;
Larson, DA ;
Malec, MK ;
McDermott, MW ;
Sneed, PK ;
Wara, WM ;
Wilson, CB .
JOURNAL OF NEUROSURGERY, 1996, 84 (03) :442-448
[5]  
Bentz M, 1998, GENE CHROMOSOME CANC, V21, P172, DOI 10.1002/(SICI)1098-2264(199802)21:2<172::AID-GCC14>3.3.CO
[6]  
2-T
[7]   Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization [J].
Bigner, SH ;
Matthews, MR ;
Rasheed, BKA ;
Wiltshire, RN ;
Friedman, HS ;
Friedman, AH ;
Stenzel, TT ;
Dawes, DM ;
McLendon, RE ;
Bigner, DD .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (02) :375-386
[8]   IDENTIFICATION OF THE HEPATOCYTE GROWTH-FACTOR RECEPTOR AS THE C-MET PROTOONCOGENE PRODUCT [J].
BOTTARO, DP ;
RUBIN, JS ;
FALETTO, DL ;
CHAN, AML ;
KMIECIK, TE ;
VANDEWOUDE, GF ;
AARONSON, SA .
SCIENCE, 1991, 251 (4995) :802-804
[9]  
BURGER PC, 1994, TUMORS CENTRAL NERVO, P25
[10]   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].
Cairncross, JG ;
Ueki, K ;
Zlatescu, MC ;
Lisle, DK ;
Finkelstein, DM ;
Hammond, RR ;
Silver, JS ;
Stark, PC ;
Macdonald, DR ;
Ino, Y ;
Ramsay, DA ;
Louis, DN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479